---
layout: default
title: Acetaminophen Cinnamon
parent: 僅模型預測 (L5)
nav_order: 107
evidence_level: L5
indication_count: 0
---

# Acetaminophen Cinnamon
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ACETAMINOPHEN; CINNAMON: From Unknown Indication to No Prediction Available

## One-Sentence Summary

ACETAMINOPHEN; CINNAMON is a combination product with no registered authorization in Taiwan and no available mechanism of action data on file.
The TxGNN model was **unable to generate any predicted new indications** for this combination, likely due to the absence of a resolvable DrugBank ID.
As a result, **no evidence** (clinical trials or publications) is available to support a repurposing assessment at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No registered indication found |
| Predicted New Indication | None (no TxGNN output) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only, no actual studies |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available, and no DrugBank ID could be resolved for this combination product. Based on general pharmacological knowledge, acetaminophen (paracetamol) is a well-established analgesic and antipyretic, while cinnamon (*Cinnamomum* spp.) is a botanical ingredient with reported anti-inflammatory and antihyperglycaemic properties in preclinical settings. However, the specific fixed-dose combination "ACETAMINOPHEN; CINNAMON" does not appear to correspond to any recognized regulatory product in the query database.

Because no DrugBank ID was successfully linked and the `predicted_indications` list returned empty, the TxGNN knowledge graph had insufficient anchor points to generate repurposing candidates. Without a valid drug node in the knowledge graph, the model cannot propagate disease associations or score candidate indications.

Until the combination is mapped to a recognized DrugBank entry (or its individual components are evaluated separately), mechanistic analysis and repurposing scoring cannot proceed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This product has **no registered authorizations** in Taiwan and no US NDA/market data on file.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** All safety fields (key warnings, contraindications, drug–drug interactions) returned no data during the current query cycle (2026-03-24). A dedicated review of individual component safety profiles—acetaminophen and cinnamon—should be conducted separately before any further evaluation.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN predictions were generated for this combination, and both the original indication and mechanism of action are unresolvable with current data. There is no foundation upon which to build a repurposing case.

**To proceed, the following is needed:**

- **Resolve DrugBank mapping**: Determine whether this combination maps to an existing DrugBank entry, or evaluate each component (acetaminophen, cinnamon extract) independently.
- **Clarify product identity**: Confirm whether "ACETAMINOPHEN; CINNAMON" is a fixed-dose combination product, a traditional/herbal medicine, or a compounded formulation — the regulatory pathway will differ significantly.
- **Retrieve MOA data**: Query DrugBank API for acetaminophen (DB00316) and any relevant cinnamon-derived compounds (e.g., cinnamaldehyde, cinnamic acid) to establish a mechanistic basis.
- **Re-run TxGNN pipeline**: Once a valid DrugBank ID is assigned, rerun the KG prediction and DL prediction steps to generate candidate indications.
- **Safety review**: Independently compile warning and contraindication data for both acetaminophen and cinnamon components before any clinical or regulatory submission.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

